Literature DB >> 17073439

Characterization of mitogen-activated protein kinase (MAPK) dimers.

Julie L Wilsbacher1, Yu-Chi Juang, Andrei V Khokhlatchev, Ewen Gallagher, Derk Binns, Elizabeth J Goldsmith, Melanie H Cobb.   

Abstract

Phosphorylated ERK2 has an increased capacity to form homodimers relative to unphosphorylated ERK2. We have characterized the nature of the ERK2 dimer and have mutated residues in the crystal dimer interface to examine the impact of dimerization on ERK2 activity. Analysis of the mutants by gel filtration indicates that at least five residues must be mutated simultaneously to produce an ERK2 mutant that is predominantly monomeric. Mutants, whether monomers or dimers, have specific protein kinase activities under fixed assay conditions that are roughly equivalent to wild-type ERK2. The ratio of dimers to monomers is increased as the salt concentration increases, consistent with a strong hydrophobic contribution to the energy of dimer formation. ERK2 dimerization also requires divalent cations. Sedimentation analysis indicates that the related c-Jun N-terminal kinase SAPKalphaI/JNK2 also forms dimers, but dimerization displays no dependence on phosphorylation; the unphosphorylated and phosphorylated forms of the kinase behave similarly, with low micromolar dimer dissociation constants.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17073439     DOI: 10.1021/bi061041w

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  13 in total

1.  Measuring the constitutive activation of c-Jun N-terminal kinase isoforms.

Authors:  Ryan T Nitta; Shawn S Badal; Albert J Wong
Journal:  Methods Enzymol       Date:  2010       Impact factor: 1.600

2.  ERK nuclear translocation is dimerization-independent but controlled by the rate of phosphorylation.

Authors:  Diane S Lidke; Fang Huang; Janine N Post; Bernd Rieger; Julie Wilsbacher; James L Thomas; Jacques Pouysségur; Thomas M Jovin; Philippe Lenormand
Journal:  J Biol Chem       Date:  2009-11-17       Impact factor: 5.157

3.  Resting and active states of the ERK2:HePTP complex.

Authors:  Dana M Francis; Bartosz Różycki; Antoni Tortajada; Gerhard Hummer; Wolfgang Peti; Rebecca Page
Journal:  J Am Chem Soc       Date:  2011-10-10       Impact factor: 15.419

Review 4.  Monomeric and dimeric models of ERK2 in conjunction with studies on cellular localization, nuclear translocation, and in vitro analysis.

Authors:  Sunbae Lee; Yun Soo Bae
Journal:  Mol Cells       Date:  2012-03-23       Impact factor: 5.034

5.  Activated ERK2 is a monomer in vitro with or without divalent cations and when complexed to the cytoplasmic scaffold PEA-15.

Authors:  Tamer S Kaoud; Ashwini K Devkota; Richard Harris; Mitra S Rana; Olga Abramczyk; Mangalika Warthaka; Sunbae Lee; Mark E Girvin; Austen F Riggs; Kevin N Dalby
Journal:  Biochemistry       Date:  2011-05-04       Impact factor: 3.162

6.  Mapping dynamic protein interactions in MAP kinase signaling using live-cell fluorescence fluctuation spectroscopy and imaging.

Authors:  Brian D Slaughter; Joel W Schwartz; Rong Li
Journal:  Proc Natl Acad Sci U S A       Date:  2007-12-12       Impact factor: 11.205

7.  Docking of PRAK/MK5 to the atypical MAPKs ERK3 and ERK4 defines a novel MAPK interaction motif.

Authors:  Espen Aberg; Knut Martin Torgersen; Bjarne Johansen; Stephen M Keyse; Maria Perander; Ole-Morten Seternes
Journal:  J Biol Chem       Date:  2009-05-27       Impact factor: 5.157

8.  Constitutive activity of JNK2 alpha2 is dependent on a unique mechanism of MAPK activation.

Authors:  Ryan T Nitta; Albert H Chu; Albert J Wong
Journal:  J Biol Chem       Date:  2008-10-21       Impact factor: 5.157

9.  Homodimerization of Nemo-like kinase is essential for activation and nuclear localization.

Authors:  Shizuka Ishitani; Kenji Inaba; Kunihiro Matsumoto; Tohru Ishitani
Journal:  Mol Biol Cell       Date:  2010-11-30       Impact factor: 4.138

Review 10.  The MEK/ERK Network as a Therapeutic Target in Human Cancer.

Authors:  Renee Barbosa; Lucila A Acevedo; Ronen Marmorstein
Journal:  Mol Cancer Res       Date:  2020-11-02       Impact factor: 6.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.